5wk3
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='5wk3' size='340' side='right' caption='[[5wk3]], [[Resolution|resolution]] 1.90Å' scene=''> | <StructureSection load='5wk3' size='340' side='right' caption='[[5wk3]], [[Resolution|resolution]] 1.90Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5wk3]] is a 12 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5WK3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5WK3 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5wk3]] is a 12 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5WK3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5WK3 FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CCL17, SCYA17, TARC ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5wk3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5wk3 OCA], [http://pdbe.org/5wk3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5wk3 RCSB], [http://www.ebi.ac.uk/pdbsum/5wk3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5wk3 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5wk3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5wk3 OCA], [http://pdbe.org/5wk3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5wk3 RCSB], [http://www.ebi.ac.uk/pdbsum/5wk3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5wk3 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[[http://www.uniprot.org/uniprot/CCL17_HUMAN CCL17_HUMAN]] Chemotactic factor for T-lymphocytes but not monocytes or granulocytes. May play a role in T-cell development in thymus and in trafficking and activation of mature T-cells. Binds to CCR4.<ref>PMID:10540332</ref> | [[http://www.uniprot.org/uniprot/CCL17_HUMAN CCL17_HUMAN]] Chemotactic factor for T-lymphocytes but not monocytes or granulocytes. May play a role in T-cell development in thymus and in trafficking and activation of mature T-cells. Binds to CCR4.<ref>PMID:10540332</ref> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | The homeostatic chemokine CCL17, also known as thymus and activation regulated chemokine (TARC), has been associated with various diseases such as asthma, idiopathic pulmonary fibrosis, atopic dermatitis and ulcerative colitis. Neutralization of CCL17 by antibody treatment ameliorates the impact of disease by blocking influx of T cells. Monoclonal antibody M116 derived from a combinatorial library shows potency in neutralizing CCL17-induced signaling. To gain insight into the structural determinants of antigen recognition, the crystal structure of M116 Fab was determined in complex with CCL17 and in the unbound form. Comparison of the structures revealed an unusual induced-fit mechanism of antigen recognition that involves cis-trans isomerization in two CDRs. The structure of the CCL17-M116 complex revealed the antibody binding epitope, which does not overlap with the putative receptor epitope, suggesting that the current model of chemokine-receptor interactions, as observed in the CXCR4-vMIP-II system, may not be universal. | ||
| + | |||
| + | Structural insights into chemokine CCL17 recognition by antibody M116.,Teplyakov A, Obmolova G, Gilliland GL Biochem Biophys Rep. 2017 Dec 9;13:27-31. doi: 10.1016/j.bbrep.2017.11.005., eCollection 2018 Mar. PMID:29264403<ref>PMID:29264403</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 5wk3" style="background-color:#fffaf0;"></div> | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Human]] | ||
[[Category: Gilliland, G L]] | [[Category: Gilliland, G L]] | ||
[[Category: Obmolova, G]] | [[Category: Obmolova, G]] | ||
[[Category: Teplyakov, A]] | [[Category: Teplyakov, A]] | ||
[[Category: Immune system]] | [[Category: Immune system]] | ||
Revision as of 06:01, 3 January 2018
CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN CCL17 AND M116 FAB
| |||||||||||
